CAV1 and Parkinson disease: Notably, the expression levels of CaM are downregulated in Parkinson’s disease and Alzheimer’s disease77,81, for which the overall inhibitory effects of DCT peptides on CaV1 and CaV1-mediated downstream signals would be even more profound due to less apoCaM competition (Fig. 8).